The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Body Weight Loss With Oral Semaglutide Is Predominantly Mediated By Effects Other Than Gastrointestinal Adverse Events
Juris J. Meier1; Rikke Mette Agesen2; Lars Bardtrum2; Alice Y.Y. Cheng3; Srikanth Deenadayalan2; Eduard Montanya4; Richard Pratley5;
1 St Josef Hospital, Ruhr-University Bochum, Bochum, Germany; 2 Novo Nordisk A/S, Søborg, Denmark; 3 St Michael's Hospital, University of Toronto, Toronto, ON, Canada; 4 Hospital Universitary Bellvitge-IDIBELL, CIBERDEM, and University of Barcelona, Barcelona, Spain; 5 AdventHealth Translational Research Institute, Orlando, FL, USA;